Koyfin Home > Directory > Health Care > Aerie Pharmaceuticals > EBIT

Aerie Pharmaceuticals EBIT Chart (AERI)

Aerie Pharmaceuticals annual/quarterly EBIT from 2012 to 2020. Earnings before interest and taxes measures the profit a company generates from its operations, making it synonymous with operating profit. By ignoring tax and interest expenses, it focuses solely on a company's ability to generate earnings from operations, ignoring variables such as the tax burden and capital structure.
  • Aerie Pharmaceuticals EBIT for the quarter ending June 06, 2020 was $-43m a -1.82% increase of 1m year over year
  • Aerie Pharmaceuticals EBIT for the last 12 months ending June 06, 2020 was $-180m a -5.41% increase of 10m year over year
  • Aerie Pharmaceuticals Annual EBIT for 2019 was $-187m a -11.87% increase of 22m from 2018
  • Aerie Pharmaceuticals Annual EBIT for 2018 was $-210m a 30.54% decrease of -64m from 2017
  • Aerie Pharmaceuticals Annual EBIT for 2017 was $-146m a 33.51% decrease of -49m from 2016
Other Income Statement Metrics:
  • Aerie Pharmaceuticals EBITDA for the quarter ending December 12, 2018 was $-51m a 21.13% decrease of -11m year over year
  • Aerie Pharmaceuticals Net Income for the quarter ending December 12, 2018 was $-51m a 20.91% decrease of -11m year over year
  • Aerie Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $7m
View Chart On Koyfin

Quarterly AERI EBIT Data

06/2020$-43m
03/2020$-44m
12/2019$-50m
09/2019$-43m
06/2019$-46m
03/2019$-48m
12/2018$-52m
09/2018$-61m
06/2018$-56m
03/2018$-41m

Annual AERI EBIT Data

2019$-187m
2018$-210m
2017$-146m
2016$-97m
2015$-75m
2014$-50m
2013$-22m
2012$-14m
2011$-14m